Generic opioids gain momentum against brand-name drugmakers

Brand-name drugmakers behind the narcotic painkillers Opana and OxyContin appear to be losing their bid to prevent the introduction of the drugs' cheaper generic versions. "We understand the value in developing appropriate abuse-resistant technology, and we want to find a way of incentivizing that," said Dr. Douglas Throckmorton of the FDA. "But we also understand the value of generics for patients."

View Full Article in:

New York Times (tiered subscription model), The